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Abstract
High-mobility group box 1 (HMGB1) is an architectural chromosomal protein and
stress  sensor  that  plays  a  critical  role  in  various  physiological  and  pathological
processes,  including  cell  death  and  survival.  Autophagy  is  the  major  pathway
involved  in  the  degradation  of  proteins  and  organelles,  maintenance  of  cellular
homeostasis, and promotion of survival during environmental stress. HMGB1 plays
an  important  location-dependent  role  in  the  regulation  of  autophagy.  Nuclear
HMGB1 contributes to mitophagy by regulation of heat shock protein beta-1 (HSPB1)
expression and cytoskeleton dynamics.  Cytoplasmic  HMGB1 is  a  novel  coiled-coil
myosin-like  BCL2-interacting  protein  (BECN1)-binding protein  in  the  induction of
autophagosome formation. Extracellular-reduced HMGB1 triggers autophagy in an
advanced  glycosylation  end  product-specific  receptor  (AGER)-dependent  manner.
HMGB1-dependent autophagy promotes chemotherapy resistance, sustains the tumor
metabolism requirement and T-cell survival, prevents polyglutamine aggregates and
excitotoxicity,  and protects  against  endotoxemia,  bacterial  infection,  and ischemia-
reperfusion  injury  in  vitro  or  in  animal  studies.  Targeting  the  HMGB1-mediated
autophagy pathway may be  required  to  address  whether  or  not  this  approach  is
therapeutically advantageous in human disease.
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1. Introduction
The autophagic network is complex and requires a core regulator: autophagy-related genes/
proteins  (ATGs)  [1].  The  study  of  the  molecular  basis  of  autophagy  started  with  the
discovery  of  Aut1  (now  Atg3)  [2],  Apg13  (now  Atg13)  [3],  and  Apg1  (now  Atg1;  the
mammalian homolog is ULK1 [unc-51 like autophagy-activating kinase 1]) [4] in Saccharo‐
myces cerevisiae in 1997. Currently, over 38 ATGs that control membrane dynamics during
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autophagy have been identified in the cells of different organisms, ranging from yeasts to
mammals [5–7].
In addition to ATGs, several non-ATG proteins are involved in the regulation of autophagy
through direct or indirect interplay with ATGs. High-mobility group protein 1 (HMGB1)
belongs to the family of the high-mobility group (HMG) nuclear proteins [8]. Here, we
highlight the emerging role of HMGB1 as an important non-ATG protein in the regulation of
autophagy.
2. HMGB1 structure
HMGB1 is a highly conserved protein and present in almost all cell types [9]. The genetic
sequence of human HMGB1 is located on chromosome 13q12–13 and the protein sequence
of human HMGB1 is composed of 215 amino acids (AAs). Human HMGB1 is 99% AA
identical to mouse, rat, bovine, and porcine HMGB1. HMGB1 structurally consists of
three different domains: two DNA-binding domains (HMG boxes A and B) and a nega-
tively charged 30 AA C-terminal region that contains only Asp and Glu. Both the HMGB1
A and B boxes are about 75–80 AAs long and are formed by two short and one long α-
helixes that upon folding, produce an L- or V-shaped three-dimensional domain structure
[10–12]. The cytokine activity of HBMG1 is restricted to the HMG B box because AA89–
108 of HMGB1 can be recognized by Toll-like receptor (TLR)-4 to induce the release of
proinflammatory cytokines [13]. In contrast, the purified recombinant A box has been
identified as an antagonistic and anti-inflammatory factor [14]. AA150–183 of HMGB1 is
responsible for binding to the receptor for advanced glycation end products (AGER/
RAGE) to induce cell migration [15]. In addition, to mediate cell migration, AGER is also
important for HMGB1-induced autophagy [16], metabolism [17], and inflammation [18] in
a context-dependent manner. AA 27–43 and 178–184 of HMGB1 contain two nuclear local-
ization signals, respectively. Acetylation of nuclear localization signals triggers HMGB1
translocation from the nucleus to the cytosol. HMGB1 is a redox protein and contains
three cysteines (C23, C45, and C106). C23 and C45 form an intramolecular disulfide bond
within the A-domain, while C106 is redox inactive and remains reduced [19, 20]. In gener-
al, reduced HMGB1 exhibits immune activity, whereas oxidized HMGB1 displays immune
tolerance [21, 22]. In addition to regulating activity, redox also affects HMGB1 transloca-
tion and release [23, 24]. For example, mutant C106 can cause HMGB1 translocation from
the nucleus to the cytosol. Indeed, oxidative stress plays a central role in mediating active
HMGB1 secretion as well as passive release [25]. Inhibition of HMGB1 release by antioxi-
dant compounds such as N-acetyl-cysteine [26], quercetin [27], edaravone [28], epigalloca-
techin gallate [29], and resveratrol [30] improves animal survival and limits the
inflammatory response in infection and tissue damage.
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3. HMGB1 function
Under normal conditions, over 95% of intracellular HMGB1 is located in the nucleus and
functions as a deoxyribonucleic acid (DNA) chaperone. Under stress conditions, HMGB1 can
be released from the intracellular to the extracellular space [31]. Extracellular HMGB1 acts as
a damage-associated molecular pattern molecule (DAMP) to mediate the inflammation,
immunity, and metabolism responses in human disease [9, 32]. Thus, the function of HMGB1
depends on its location. Below, we summarize the major functions of nuclear, cytosolic, and
extracellular HMGB1, respectively.
3.1. Nuclear HMGB1
Like the histones, HMGB1 is among the most important chromatin proteins. In particular, the
DNA-binding domains confers HMGB1 the ability to recognize, bind, and bend different DNA
structures such as DNA mini-circles, four-way junctions, looped structures, hemicatenated
DNA, and triplex DNA [33]. This DNA chaperone activity is critical for HMGB1-mediated
nuclear homeostasis and genome stability.
3.1.1. Nucleosome dynamics and quantity
The nucleosome is the fundamental subunit of chromatin. Each nucleosome is composed of a
core particle, DNA, and a linker protein. The proteins in the core particle and linker proteins
are called histones. HMGB1 can bind to histones and DNA to promote nucleosome sliding,
relax nucleosome structure, and make chromatin more accessible [34, 35]. Loss of HMGB1
leads to the loss and release of nucleosomes [36, 37]. Extracellular nucleosomes, including
histones and DNA, are inflammatory mediators in cancer, sepsis, and pancreatitis [38].
3.1.2. Gene transcription
HMGB1 knockout mice die shortly after birth due to hypoglycemia and exhibit a defect in the
transcriptional enhancement of the glucocorticoid receptor [39]. In addition to the glucocorti-
coid receptor, HMGB1 interacts with a number of transcription factors (e.g., p53, p73, the
retinoblastoma protein, nuclear factor kappa B [NF-κB], and estrogen receptor) to either
activate or repress the transcription of specific genes.
3.1.3. DNA repair
The major forms of DNA damage include single-strand breaks, double-strand breaks, altera-
tion of bases, hydrolytic depurination, hydrolytic deamination of cytosine and 5-methylcy-
tosine bases, formation of covalent adducts with DNA, and oxidative damage to bases and
to the phosphodiester backbone of DNA. Loss of HMGB1 increases these lesions [40, 41] and
nuclear HMGB1 contributes to base excision repair, nucleotide excision repair, and mis-
match repair [33].
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3.1.4. V(D)J recombination
VDJ recombination is the process by which T cells and B cells randomly assemble different
gene segments—known as variable (V), diversity (D), and joining (J) genes—in order to
generate unique receptors (known as antigen receptors) that can collectively recognize many
different types of molecules. HMG proteins, including HMGB1, are important components of
the V(D)J recombinase complex [42].
3.1.5. Telomere homeostasis
Telomeres are caps with a region of repetitive nucleotide sequences at the end of chromosomes.
Telomerase is an enzyme made of protein and ribonucleic acid (RNA) subunits that elongates
chromosomes by adding TTAGGG sequences to the end of existing chromosomes. Telomere
shortening is involved in the aging process. Loss of HMGB1 reduces telomerase activity,
decreases telomere length, and increases chromosomal stability on a cellular level [43, 44].
3.2. Cytosolic HMGB1
Early studies have shown that the expression of HMGB1 in hepatic and brain tissues is high;
it has been suggested a functional role of HMGB1 in both the nucleus and the cytoplasm [45,
46]. Recent studies have demonstrated that various tissues have a near-universal high expres-
sion of HMGB1. Cytoplasmic localization of HMGB1 has been observed in living fibroblasts
[47], thymocytes [48], and several different tissues (e.g., liver, kidney, heart, and lung) [49].
Normally, the nuclear-to-cytoplasmic HMGB1 ratio is about 30:1 and this ratio is significantly
reduced in cellular stress [49]. HMGB1 translocates from the nucleus to the cytoplasm,
including the mitochondria and lysosomes, following various types of stressors such as
inflammatory cytokines/chemokines and thermal and hypoxic stress. Although the study of
the function of cytosolic HMGB1 remains poor, our research indicates that the main function
of HMGB1 in the cytoplasm is to function as a positive regulator of autophagy and mitophagy
(discussed later at section 4.2).
3.3. Extracellular HMGB1
HMGB1 can be actively secreted by immune cells or passively released by dead, dying, or
injured cells [50]. Extracellular HMGB1 has multiple functions and is involved in several
processes.
3.3.1. Cell differentiation
The first reported activity of extracellular HMGB1 is that HMGB1 promotes murine erythro-
leukemia cell differentiation [51, 52]. Structurally, the N-terminal region of HMGB1 is respon-
sible for promoting murine erythroleukemia cell differentiation [53]. In addition to murine
erythroleukemia cells, extracellular HMGB1 triggers the differentiation of chronic lymphocytic
leukemia, stem cells, dendritic cells (DCs), and T cells [54, 55].
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3.3.2. Inflammation and immunity
HMGB1 is an important late mediator released by macrophages in sepsis [31]. In addition to
macrophages, many immune cells (e.g., neutrophils, mast cells, eosinophils, DCs, T cells, and
natural killer cells) can release HMGB1 in response to infection [56]. HMGB1 cannot be actively
secreted via the classical endoplasmic reticulum -Golgi secretory pathway due to lacking a
leader signal sequence [57]. In turn, secretory lysosome contributes to HMGB1 secretion [58].
This process is regulated by metabolism [59]. Once released, HMGB1 can activate immune
cells to sustain the inflammatory response. This process is regulated by redox status, receptor,
and partner of HMGB1. For example, HMGB1 can bind and activate different signaling
transduction cell receptors such as AGER, TLRs (e.g., TLR-2, -4, and -9), CD24, and TIM3 [60–
62]. HMGB1 is very “sticky” and can bind to various extracellular pathogen-associated
molecular patterns (PAMPs) (e.g., lipopolysaccharide) and DAMPs (e.g., DNA and histones)
to amply inflammatory and immune responses [60, 63].
3.3.3. Cell migration
HMGB1 has chemokine activity to induce cell invasion and migration, a key process during
the development of most organisms [64]. The potential mechanism includes HMGB1-mediated
signaling transduction (e.g., ERK [65, 66] and Cdc42 [67]), transcriptional factor activation (e.g.,
NF-κB), and chemokine production.
3.3.4. Tissue regeneration
Tissue regeneration is the body’s autohealing reaction once it gets injured or damaged. HMGB1
can stimulate myocardial regeneration, which may facilitate cardiac repair [68–71], cardio-
myocyte hypertrophy [72], or cardiac fibrosis [73].
3.3.5. Angiogenesis
Angiogenesis is the growth of blood vessels from the existing vasculature. Treatment with
HMGB1 protein increases angiogenesis by the secretion of vascular endothelial growth factor,
an important inducer of angiogenesis [74].
4. HMGB1 and autophagy
4.1. Nuclear HMGB1 in autophagy
Mitophagy is an important mitochondrial quality control mechanism to sustain mitochondrial
structure and function. We recently demonstrated that the nuclear protein HMGB1 modulates
mitochondrial respiration and morphology by sustaining mitophagy through the regulation
of heat shock protein β-1 (HSPB1) gene expression [75]. Metabolic activities in normal cells
rely primarily on mitochondrial oxidative phosphorylation (OXPHOS) to generate adenosine
triphosphate (ATP) for energy. In contrast, cancer cells mainly use glycolysis to generate ATP
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for energy. This type of energy reprogramming is called the Warburg effect. Interestingly,
knockout or knockdown of HMGB1 or HSPB1 significantly inhibits OXPHOS and glycolysis
in cancer cells or fibroblasts [75]. As expected, ATP production is decreased in HMGB1- or
HSPB1-deficient cells. HSPB1 is a member of the small heat shock proteins (HSPs), which are
important for protein folding [75]. HSPB1, but not other HSPs, is significantly inhibited in
HMGB1-/-cells. Transfection of HMGB1 complementary DNA (cDNA) into HMGB1 cells
restores HSPB1 expression at messenger RNA (mRNA) and protein levels. This process is not
dependent on heat shock factor 1 (HSF1), the major transcription factor for HSP expression.
Importantly, forced expression of HSPB1 by gene transfection corrects the deficiency in
mitochondrial respiration, ATP production, and mitochondrial fragmentation, which is
observed in HMGB1-deficient cells [75]. Thus, HSPB1 is the primary downstream mediator of
HMGB1’s effect on the regulation of mitochondrial homeostasis.
Alterations to the cytoskeleton during cell death and autophagy have been described in a
variety of different cells. Previous studies have suggested that HSPB1 has a direct influence
on the dynamics of cytoskeletal elements by HSPB1 phosphorylation [76, 77]. Similarly, by
using cytoskeleton inhibitor cytochalasin D, loss of HSPB1 or mutation of its phosphorylation
sites at serines 15 and 86 decreases starvation and rotenone-induced autophagy and mitophagy
and impairs autophagosome and lysosome fusion [75]. These findings suggest that impaired
cytoskeleton is involved in HMGB1-HSPB1 pathway-mediated mitophagy.
PTEN-induced putative kinase-1 (PINK1) is a kinase of the outer mitochondrial membrane,
and PARK2 is a protein implicated in autosomal recessive juvenile Parkinsonism. The PINK1-
PARK2 pathway has been largely implicated in the removal of damaged mitochondria with
depolarized membranes in mammalian cells [78]. Upon mitochondrial membrane depolari-
zation, PINK1 mediates the stress-induced mitochondrial translocation of PARK2. Subse-
quently, mitochondrial PARK2 drives the formation of Lys27-linked ubiquitin chains on the
outer membrane of voltage-dependent anion channel 1 (VDAC1) [78]. These chains are then
recognized by the autophagic adapter protein sequestosome 1 (SQSTM1/p62). SQSTM1 binds
directly to LC3 to facilitate the formation of autophagosomes engulfing damaged mitochon-
dria. HMGB1 and HSPB1 regulate PARK2 translocation and VDAC1 ubiquitination during
mitochondrial depolarization. Knockdown of PINK1 or PARK2 abolishes the HSPB1-induced
restoration in ATP production and reduction in mitochondrial fragmentation in HMGB1-
deficient cells. Collectively, activation of the PINK1-PARK2 pathway is required for the
HMBG1-HSPB1-dependent autophagic clearance of mitochondria. HMGB1 and HSPB1
translocate into the mitochondria during cellular stress. Whether these proteins interact
directly with PINK1 or PARK2 remains unknown.
4.2. Cytosolic HMGB1 in autophagy
Release of HMGB1 has been observed in different types of cell death such as apoptosis,
necrosis, and necroptosis [50, 79–84]. Similarly, classical autophagic stimuli such as rapamycin
or starvation trigger HMGB1 translocation and release [81]. This process is not associated with
lactate dehydrogenase release in the early stage, suggesting that translocation and release of
HMGB1 in autophagy is an active process. Reactive oxygen species (ROS) generated in cell
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stress induce cell death, survival, or senescence, depending on the concentration of ROS. ROS
quencher (e.g. N-acetyl cysteine) inhibits starvation- and rapamycin-induced HMGB1 trans-
location and subsequent autophagy [81]. Knockdown of antioxidant enzyme superoxide
dismutase 1 also promotes HMGB1 cytosolic translocation and release in autophagy [85].
These findings suggest that oxidative stress is required for the translocation and release of
HMGB1 in autophagy.
BECN1 was originally discovered as a Bcl-2-interacting protein. Bcl-2 binds to BECN1, leading
to repression of autophagy [86]. We now know that BECN1 participates in autophagosome
formation and plays an important role in the regulation of interplay between autophagy and
apoptosis [87]. The levels of HMGB1 affect the interaction between Bcl-2 and BECN1 in
autophagy. On one hand, HMGB1 is involved in the regulation of Bcl-2 phosphorylation by
activation of the ERK pathway. Ablation of HMGB1 diminishes starvation-induced phosphor-
ylation of both ERK1/2 and Bcl-2 [87]. Phosphorylation of Bcl-2 inhibits interaction between
Bcl-2 and BECN1. On the other hand, cytosolic HMGB1 has been identified as a direct BECN1-
binding protein in tumor and nontumor cells. HMGB1 competes with Bcl-2 for interaction with
BECN1 and orients BECN1 to autophagosomes in response to starvation. Structurally, C23 and
C45 are required for HMGB1 to bind to BECN1 [87]. Mutation of C23 and C45 in HMGB1
results in the loss of their ability to mediate autophagy. Moreover, C106S mutation of HMGB1
results in much higher cytoplasmic levels of HMGB1 and demonstrates enhanced binding to
BECN1, leading to the subsequent dissociation of Bcl-2 from BECN1. Knockdown of HMGB1
finally inhibits the formation of the BECN1- PIK3C3 complex in autophagy.
In addition to the redox state of HMGB1, several proteins such as ULK1, FIP200, nuclear
accumbens-1 (NAC1), p53, SNCA/α-synuclein, and gamma-interferon inducible lysosomal
thiol reductase (GILT) have been demonstrated to positively or negatively regulate HMGB1-
BECN1 complex formation in several cells.
Different from other ATGs, ULK1 is a serine/threonine-protein kinase. FIP200 (FAK family
kinase-interacting protein of 200 kDa) was identified in a two-hybrid screen with the tyrosine
kinase Pyk2. Both ULK1 and FIP200 are involved in the formation of ULK1-ATG13-FIP200
complex in triggering vesicle nucleation during autophagy [88–91]. The formation of the
ULK1-ATG13-FIP200 complex is not affected by HMGB1. However, knockdown of ULK1 or
FIP200 inhibits HMGB1-BECN1 complex formation. This increases cell death in osteosarcoma
cells following anticancer agent treatment [92]. Thus, the HMGB1-BECN1 complex functions
as a downstream signal from ULK1-mATG13-FIP200 complex formation in the induction of
autophagy.
NAC1 is a nuclear protein that belongs to the POZ/BTB (Pox virus and zinc finger/bric-a-brac
tramtrack broad complex) domain family. NAC1 can bind and increase HMGB1 translocation
from the nucleus to the cytosol and subsequent HMGB1-BECN1 complex formation in
response to cisplatin [93]. Suppression of NAC1 expression limits HMGB1-BECN1 complex
formation and impairs the autophagic response and enhanced anticancer activity of cisplatin
in tumor cells [93].
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p53, the most common tumor suppressor, plays both transcription-dependent and -independ-
ent roles in the regulation of apoptosis, autophagy, metabolism, cell cycle progression, and
many other processes. Cytosolic p53 is a negative regulator of autophagy through a transcrip-
tion-independent mechanism [94] whereas nuclear p53 is a positive regulator of autophagy by
a transcription-dependent mechanism [95, 96]. A number of studies have demonstrated a
nuclear interaction between HMGB1 and p53 in the regulation of gene expression [97–100].
The interaction between HMGB1 and p53 in the nucleus and cytosol is increased in colon cancer
cells following starvation-induced autophagy [101]. Importantly, p53-HMGB1 complexes
regulate cytosolic translocation of the reciprocal protein and levels of autophagy. Loss of p53
increases HMGB1 cytosolic translocation and HMGB1- BECN1 complex formation, which
results in autophagy induction [101]. In contrast, loss of HMGB1 increases p53 cytosolic
translocation, which leads to autophagy inhibition [101]. This dynamic location change
between p53 and HMGB1 affects the levels of autophagy and anticancer activity of chemo-
therapy in colon cancer cells [102].
SNCA is expressed predominantly in the brain, where it is concentrated in presynaptic nerve
terminals. The deposition of the abundant presynaptic brain protein SNCA as an aggregating
fibrillary in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative
disorders. Autophagy contributes to SNCA clearance. Interestingly, aggregated SNCA may
inhibit autophagy by blocking the cytosolic translocation of HMGB1 and subsequent HMGB1-
BECN1 binding in PC12 cells [103]. Thus, HMGB1 may be a new target for drug intervention
to restore the deficient autophagy caused by SNCA in neurodegenerative disorders.
GILT is a lysosomal thiol reductase, which can reduce protein disulfide bonds at a low pH.
The enzyme is expressed constitutively in antigen-presenting cells (e.g., B cells, DCs, mono-
cytes, and macrophages) and is induced by γ interferon in endothelial cells and tumor cells.
GILT may negatively regulate HMGB1-BECN1 complex formation in response to oxidative
stress [104]. Loss of GILT increases the cytosolic translocation of HMGB1 and subsequent
autophagy, which contributes to diminished superoxide dismutase 2 expression and elevated
superoxide production.
4.3. Extracellular HMGB1 in autophagy
HMGB1 release is a critical regulator of apoptosis and autophagy in response to metabolic and
therapeutic stress [105]. Treatment with reduced but not oxidized HMGB1 protein increases
the accumulation of LC3 puncta associated with induced LC3-II formation, reduced expression
of SQSTM1, and suppressed BECN1-Bcl-2 complex formation [16]. However, the HMGB1
C106A mutant protein significantly decreases autophagy compared with wild-type reduced
HMGB1 protein [16]. Moreover, knockout of BECN1 inhibits reduced HMGB1-induced
autophagy, suggesting that BECN1 is required for reduced HMGB1-induced autophagy.
Interestingly, oxidized HMGB1 may trigger mitochondria-mediated apoptosis by activation
of CASP-3 and -9 [16].
Multiple surface receptors, including TLR2, TLR4, and AGER have been demonstrated to
mediate HMGB1 activity. C106 is required for HMGB1 binding to TLR4 and activation of
cytokine release in macrophages. AGER is a transmembrane receptor of the immunoglobulin
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gene superfamily encoded within the class III region of the major histocompatibility locus.
RAGE activation has been implicated in infection and sterile inflammation, as well as in cancer,
diabetes, and Alzheimer’s disease. The interaction between AGER and its ligands, including
HMGB1, promotes proinflammatory signal pathway activation and the formation of neutro-
phil extracellular traps partly through upregulation of autophagy [17, 106, 107]. AGER
promotes anticancer agent-induced autophagy by regulating MTOR activation and BECN1-
PIK3C3 complex formation [108, 109]. Knockdown of AGER, but not TLR4 in cancer cells
diminishes HMGB1-induced autophagy [16]. Moreover, AGER contributes to HMGB1-
induced autophagy in a BECN1-dependent manner in cancer cells. However, it is unclear
which receptor is required for oxidized HMGB1-induced apoptosis. In addition to HMGB1,
AGER is required for IL6- and hypoxia-induced autophagy in pancreatic cancer cells, sug-
gesting an important role of RAGE-mediated autophagy in the pancreatic tumor microenvir-
onment [106, 110].
5. Transcriptional regulation of HMGB1 in autophagy
Transcription factors such as p53 [111], c-Myc [112], and Kruppel-like factor-4 [113] have been
reported to regulate mRNA expression of HMGB1 in several cells. These transcription factors
are also important for autophagy. In addition to transcription factors, microRNAs (miRNAs)
play an important role in the regulation of HMGB1 expression. miRNAs are a class of post-
transcriptional regulators of gene expression. They are short (about 22 nucleotide) RNA
sequences that bind to complementary sequences in the 3' untranslated region (3'UTR) of
multiple target messenger RNAs (mRNAs). At the molecular level, miRNAs restrain the
production of proteins by affecting the stability of their target mRNA and/or by downregu-
lating their translation. We recently demonstrated that MIR34A is a potent inhibitor of
autophagy by suppression of HMGB1 (but not sirtuin 1) expression in the retinoblastoma cell
[114]. MIR34A directly targets HMGB1 mRNA and inhibits HMGB1 protein levels, thereby
preventing autophagosome activation [114]. Targeting the MIR34A-HMGB1 pathway inhibits
autophagy and increases apoptosis in response to chemotherapy.
Another study suggests that MIR22 controls autophagy by regulating HMGB1 protein levels
[115]. MIR22 is an evolutionally conserved miRNA that is highly expressed in various tissues
and cancer cells. MIR22-mediated transcriptional regulation of HMGB1 inhibits autophagy
and chemotherapy resistance in osteosarcoma cells [115]. The human let-7 family of micro-
RNAs contains 13 members that are major players in the regulation of gene expression. HMGB1
is another important direct target of MIR-let-7f-1 in medulloblastoma cells [116]. Overexpres-
sion of MIR-let-7f-1 inhibits HMGB1 expression and subsequent autophagy in medulloblas-
toma cells following treatment with cisplatin [116]. The complex interactions of HMGB1
expression by miRNAs and transcription factors in autophagy must be further investigated
and will likely impact tumor treatment in the future.
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6. Post-translational modification of HMGB1 in autophagy
Autophagy is mainly regulated by post-translational and lipid modifications of ATG pro-
teins. HMGB1 also undergoes extensive post-translational modifications, including reversi-
ble and terminal acetylation [117], poly-ADP-ribosylation [118, 119], phosphorylation
[120], and oxidation [121]. These post-translational modifications have been demonstrated
to influence HMGB1’s DNA chaperone activity, subcellular localization, and extracellular
DAMP activity. We have discussed above that the redox status of HMGB1 affects autoph-
agy. Unlike other members of the tumor necrosis factor (TNF) superfamily, the TNF (li-
gand) superfamily, member 10 (TNFSF10/TRAIL) selectively activates CASP8 and induces
apoptosis in cancer cells (but not normal cells) in vitro and in vivo. HMGB1 is specifically
poly-ADP-ribosylated (PAR) by PAR polymerase-1 (PARP1) in pancreatic cancer cells.
This HMGB1 modification contributes to TNFSF10 resistance through upregulation of au-
tophagy and suppression of apoptosis [122]. PARP1 is an ADP-ribosylating enzyme criti-
cal for initiating various forms of DNA repair in nucleus. Activation of PARP1 mediates
TNFSF10-induced poly-ADP-ribosylation and subsequent translocation of HMGB1 from
the nucleus to the cytosol. Inhibition of PARP1 expression or activity via shRNA knock-
down or pharmacologic inhibitor PJ-34 significantly limits TNFSF10-induced poly-ADP-ri-
bosylation and the subsequent cytoplasmic translocation of HMGB1 in human pancreatic
cancer cells [122]. Importantly, activation of PARP1 promotes HMGB1-BECN1 complex
formation, which leads to autophagy following TNFSF10 treatment. Transfection of
HMGB1 C106S mutant cDNA into PARP1-knockdown cancer cells increases cytosolic
HMGB1 level, LC3-II expression, and TNFSF10 resistance. These findings suggest that cy-
toplasmic HMGB1 is sufficient to trigger autophagy and TNFSF10 resistance in PARP1-de-
ficient cancer cells [122]. Compared with C106S mutation, the C23S and C45S mutations
fail to restore TNFSF10-induced HMGB1-BECN1 complex formation, LC3 turnover, and
resistance to apoptosis in HMGB1-knockdown pancreatic cancer cells. Thus, PARP1-
HMGB1-BECN1-mediated autophagy inhibits TNFSF10-induced apoptosis by suppression
of CASP8 activity [122]. It will be interesting to test whether other post-translational mod-
ifications of HMGB1 directly activate autophagy under stress.
7. HMGB1-mediated autophagy in disease
The role of autophagy in cancer is complex and is likely dependent on tumor type and stage
[123]. On one hand, autophagy plays a tumor suppressor role by preventing genome instability,
limiting oxidative injury, reducing the inflammatory response, and inhibiting angiogenesis.
On the other hand, autophagy functions as a survival mechanism in tumor development.
Upregulation of autophagy promotes the growth of established tumors by sustaining energy
metabolism and cell proliferation. In addition, increased autophagy leads to therapy resistance
by diminishing regulated cell death. A number of studies indicate that HMGB1-mediated
autophagy can enable tumor cell survival by inhibition of apoptosis, which can lead to
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therapeutic resistance [92, 93, 102, 122, 124–130]. It remains to be determined whether HMGB1-
mediated autophagy contributes to the suppression of tumorigenesis [131, 132].
Autophagy regulates inflammation through interfering with innate immune signaling
pathways, including inflammasome activation and proinflammatory cytokine release [133,
134]. We and others have demonstrated that activation of autophagy contributes to HMGB1
release in immune and nonimmune cells [84]. Inflammasomes are protein complexes in the
innate immune system that regulate the activation of CASP1 or CASP11 and induce IL-1β and
IL-18 release in response to infection or tissue injury. Conditional depletion of HMGB1 in
myeloid cells renders mice more sensitive to Listeria monocytogenes infection and endotoxic
shock [135] partly through downregulation of autophagy. This in turn promotes inflamma-
some activation and IL-1β release in macrophages [135]. Cytosolic HMGB1 in intestinal
epithelial cells suppresses inflammation-associated cellular injury by controlling the switch
between the proautophagic and proapoptotic functions of BECN1 and ATG5 during inflam-
mation [136]. Moreover, conditional knockout of HMGB1 in the pancreas and liver promotes
pancreatitis [137] and liver ischemic reperfusion [138], which are sterile inflammatory diseases
without infection. Additionally, HMGB1 and BECN1 are co-expressed in the invading T cells
in the muscle tissue of myositis patients, which is required for T-cell survival and function
[139]. The underlying molecular mechanism of HMGB1-mediated autophagy in inflammation
and immunity remains to be further explored.
Most neurodegenerative diseases that afflict humans are associated with the intracytoplas-
mic deposition of aggregate-prone proteins in neurons and with autophagy dysfunction.
Impairment of HMGB1-mediated autophagy has been implicated in the increased protein
misfolding and aggregation in neurodegenerative disease [140, 141]. In addition, HMGB1
has recently been indicated to be involved in the autophagy inhibition caused by SNCA
overexpression, implying a direct role in modulating the autophagic degradation of
SNCA [103].
8. Conclusion
HMGB1 is a nuclear protein and stress sensor that plays a critical role in various physiological
and pathological processes, including autophagy. Autophagy is the major pathway involved
in the degradation of proteins and organelles, cellular remodeling, and survival during stress.
HMGB1 plays important intranuclear, cytosolic, and extracellular roles in the regulation of
autophagy [142]. Cytoplasmic HMGB1 is a novel BECN1-binding protein active in autophagy.
Extracellular HMGB1 induces autophagy in an AGER-dependent manner. Nuclear HMGB1
contributes to mitophagy by regulation of HSPB1 expression. HMGB1-dependent autophagy
promotes chemotherapy resistance, [92, 93, 101, 108, 114, 127, 128, 143–145], sustains the tumor
metabolism requirement [16, 146] and T-cell survival, [139], prevents polyglutamine aggre-
gates [140] and excitotoxicity [141], and protects against endotoxemia, bacterial infection, and
ischemia-reperfusion injury [135, 147–149]. The role of HMGB1 in autophagy is clearly
complex and tissue dependent [142]. HMGB1 is not required for starvation-induced autophagy
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in mice with hepatocyte-specific HMGB1 deletion, suggesting that an HMGB1-independent
autophagy pathway exists in different organs [150]. Indeed, mice with hepatocyte-specific
HMGB1 deletion have a different phenotype following different stressors [151, 152]. Targeting
the HMGB1-mediated autophagy pathway may be required to address whether or not this
approach is therapeutically advantageous in human disease.
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